Priothera Receives R&D Innovation Loan from Bpifrance
Summary
€1.5 million loan will further support clinical manufacture of mocravimod for the adjunctive treatment of Acute Myeloid Leukemia (AML) DUBLIN and SAINT-LOUIS, France, April 4, 2022 /PRNewswire/ -- Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announces that it has entered a €1.5 million Loan Agreement with the regional Bpifrance in Strasbourg (Grand Est Bpifrance), via Priothera SAS, its French affiliate. The Bpifrance loan will support Priotheras key objective of establishing human proof of concept and generating registrational data, allowing the company to create significant socio-economic value in France and beyond that for patients globally." Mocravimod, a sphingosine 1 phosphate (S1P) receptor modulator which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of HSCT in patients with AML. S1P receptor modulators are known to largely reduce egress of T cells from lymphatic tissues and not being immunosuppressants, thereby allowing for inhibition of graft-versus-host-disease (GvHD) while maintaining graft-versus-leukemia benefits in patients receiving HSCT. For more information please visit: www.priothera.com Bpifrance is the one stop shop for entrepreneurs with a vastly comprehensive toolbox offered in the field to customers through 50 local branches.